We’re thrilled to share that Glooko will be exhibiting at the 25th Annual Diabetes Technology Meeting (DTM), co-presented by the Diabetes Technology Society (DTS) and the American Diabetes Association, from October 28 to 30 in San Francisco, California.
At the diabetes industry event, we’ll showcase how our cutting-edge digital health platform is transforming care for people living with diabetes and their healthcare providers. Team Glooko is also looking forward to connecting with leading experts and innovators from around the globe as they explore the latest advancements shaping the future of diabetes technology.
Some of the exciting features and happenings that attendees will see at booth #15:
- New Glooko Clinic Dashboard: The dashboard, designed for busy healthcare providers, offers a clear, organized view of patient trends and key clinic metrics based on TIDE metrics developed by Stanford. This new tool helps care teams interpret complex data at-a-glance, allowing them to make more efficient decisions for their patients with diabetes and develop a more effective clinic strategy.
EndoTool Glucose Management System, developed by Monarch Medical Technologies, a Glooko Company: EndoTool, recently acquired by Glooko, is the only patient-specific insulin dosing system designed to simplify glycemic management in hospitals. Its unique algorithm models each patient’s clinical characteristics and response to insulin, delivering optimal dosing recommendations to reduce the risk of severe hypoglycemia.- Industry-Leading Device Compatibility: Glooko seamlessly connects to an extensive ecosystem of more than 200 diabetes and health monitoring devices and apps, allowing people with diabetes to sync and share their health data with their care teams to enable better treatment decisions.
- EHR Integrations: Glooko integrates with leading EHR systems to securely centralize diabetes data, eliminating the need for healthcare providers to switch platforms. This innovative functionality allows care teams to work more efficiently using a single interface with a complete view of their patients’ health data.
Expert Insights on the Power of Diabetes Health Data
Don’t miss the Actionable Data presentation given by Glooko Chief Medical and Strategy Officer Mark Clements, MD, PhD, at 1:30 p.m. PT on October 28. The presentation will offer deep insights into leveraging data to drive better outcomes in diabetes care.
Temple Health to Present New Data on Patient-Specific Subcutaneous Insulin Dosing
A highly anticipated poster,”Safety and Efficacy of a Patient-Specific Inpatient Dosing Application for Subcutaneous Insulin,” will present new evidence from Temple University Health System and Lewis Katz School of Medicine supporting the safety and efficacy of patient-specific insulin dosing for hospitalized patients on subcutaneous insulin. This study highlights outcomes from using the EndoTool SubQ application from Monarch Medical Technologies. The poster will be revealed at 4:30 p.m. PT on October 28.
Enhance Connected Care with Glooko
To find out more about our diabetes management platform from one of our experts at DTM 2025, schedule a meeting.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.